Polio
Poliomyelitis (polio) is a potentially paralysing, vaccine preventable, viral infection. The virus is transmitted through food or water contaminated by infected human faeces or by direct contact with an infectious person.
Polio is extremely rare in UK travellers with the last imported case occurring in 1993. Those at increased risk include travellers visiting friends and relatives, those in direct contact with an infected person, long-stay travellers, and those visiting areas of poor sanitation.
In 1988 polio commonly occurred in more than 125 countries on five continents, with more than 1,000 children paralysed every day. Since the launch of the Global Polio Eradication Initiative in 1988, worldwide rates of polio have been reduced by more than 99 percent. The number of countries where polio commonly occurs has declined from 125 to two: Afghanistan and Pakistan. The rest of the world remains at risk of polio importation, with a number of countries still reporting imported cases of polio.
Most individuals (about 95 percent) who acquire polio do not develop symptoms. When they do occur symptoms may range from a mild illness with fever, to symptoms of meningitis (inflammation of the lining of the brain) or paralysis. Although paralysis occurs in less than one percent of infections it is frequently long lasting.
Prevention
An effective vaccination against polio is available. In addition to vaccination travellers should ensure good personal hygiene and follow advice on prevention of food and water-borne diseases.
Polio vaccine
The objective of the immunisation programme is to provide a minimum of five doses of a polio-containing vaccine at appropriate intervals for all individuals. For adults and children from 10 years of age, who have not received polio vaccinations in the past, a three dose course of vaccinations can be provided.
Polio vaccine is recommended for:
- All individuals, from two months of age as part of the UK routine immunisation schedule.
- Travellers to areas or countries where there are recent reports of wild polio (see) and their last dose of polio vaccine was given 10 or more years ago.
- Individuals at risk of exposure to polio through their work, e.g. certain healthcare workers and microbiology laboratory staff.
- Certain groups of individuals travelling to countries affected by the WHO temporary recommendations that were initially implemented in May 2014.
In September 2004, inactivated polio vaccines (IPV) replaced oral polio vaccine (OPV) in UK routine vaccine schedules.
Vaccination schedules
| Vaccine | Schedule and age range |
| The 6-in-1 vaccine: diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type b and hepatitis B (DTaP/IPV/Hib/HepB) | Three doses: given at 8, 12 and 16 weeks of age and a fourth dose at 18 months of age |
| The 4-in-1 vaccine: diphtheria, tetanus, acellular pertussis and polio (dTaP/IPV) | Single pre-school booster dose: given at 3 years, 4 months old or soon after |
| The 3-in-1 vaccine: tetanus, diphtheria and polio (Td/IPV) | Single booster dose: given at 13/14 years of age A low dose diphtheria-containing vaccine should be offered to anyone aged 10 years or over whether they require the vaccine as part of a primary course or as a booster |
| Diphtheria, tetanus, and acellular pertussis (Tdap) From July 2024, a non-polio (IPV) containing pertussis vaccine is preferred but the diphtheria, tetanus, acellular pertussis, polio vaccine (dTaP/IPV) can be used for pregnant women if Tdap is contraindicated or unavailable [8] |
Single booster dose: offered to pregnant women 16 to 32 weeks gestation* |
*Recommended for pregnant women between 16 to 32 weeks to protect unborn child against whooping cough (pertussis). Women may still be immunised after week 32 of pregnancy, but this may not offer as high a level of protection to the baby.
Length of protection
In most circumstances five doses of polio containing vaccine at the appropriate intervals is considered to give satisfactory long-term protection for life in the UK. However travellers to areas or countries where there are recent reports of polio and whose last dose of polio vaccine was 10 or more years ago should be offered a booster dose of a polio containing vaccine. See our Country Information pages for individual country recommendations.
Resources
- More detailed information can be found in our polio factsheet
- Polio vaccination certificate
- UKHSA: Immunisation against infectious disease. Polio
- UKHSA: Polio: guidance, data and analysis
- Further details on the vaccines can be found on the Summary of Product Characteristics (SPC) on the electronic medicines compendium
- WHO: Polio
- WHO: Polio eradication initiative
Explore more
West Nile virus
West Nile virus (WNV) is a type of flavivirus (like dengue or Zika) that can cause a potentially serious infection in humans.
Oropouche virus disease
Oropouche virus disease is an arboviral disease caused by the Oropouche virus (OROV) spread to humans mainly through the bite of an infected midge
Measles
Measles is a highly infectious viral illness with the potential for serious and life-threatening complications
Chikungunya
Chikungunya is a viral infection caused by the chikungunya virus (CHIKV) and is transmitted through the bite of an infected mosquito
Rabies
Rabies is transmitted to humans usually by a bite or scratch from an infected animal (usually a dog) and almost always fatal once symptoms appear
Recent News on Polio
Polio: Public Health Emergency of International Concern
An update on the polio Public Health Emergency of International Concern (PHEIC)
Updated: 31 July 2025Recent Polio Outbreaks
cVDPV1 in Israel
Between February and July 2025, nine genetically linked circulating vaccine-derived polio virus type 1 (cVDPV1) positive environmental samples were reported from seven sites in Israel, mainly in Jerusalem and the Central Region. Please see our Topics in Brief article for more details on polio.
cVDPV2 in Germany
In the week ending 6 August 2025, eight circulating vaccine-derived polio virus type 2 (cVDPV2)-positive environmental samples were reported in Germany; one from Baden, three from Bayern, one from Rheinland, and three from Sachsen. Please see our Topics in Brief article for more details on polio.
cVDPV2 in Central African Republic
On 25 March 2025, one environmental sample of circulating vaccine-derived poliovirus type 2 (cVDPV2) was confirmed in Central African Republic. Please see our Topics in Brief article for more details on polio.
cVDPV3 in Cameroon
As of 16 July 2025, one circulating vaccine-derived poliovirus type 3 (cVDPV3) case was reported this week, with onset of paralysis on 30 May 2025. Laboratory investigations are ongoing to determine its origin. Please see our Topics in Brief article for further details on polio.
